曲安奈德与雷珠单抗治疗继发性黄斑水肿的比较

目的 比较后部眼球筋膜下注射曲安奈德与玻璃体内注射雷珠单抗对视网膜中央静脉阻塞继发黄斑水肿的疗效.方法 回顾性分析郑州市第七人民医院2016年6月至2019年6月60例(60眼)视网膜中央静脉阻塞继发黄斑水肿的资料.所有患者分为雷珠单抗组和曲安奈德组,每组30例(30眼).分别进行雷珠单抗玻璃体内注射及曲安奈德后部眼球...

Comparison between triamcinolone acetonide and rannibizumab for the treatment of secondary macular edema

Objective To compare the efficacy between intravitreal injection of ranibizumab and injection of triamcinolone acetonide(TA)under posterior tenon's capsule for the treatment of macular edema secondary to central retinal vein occlusion(CRVO).Methods The clinical data of 60 eyes of 60 patients with secondary macular edem a due to CRVO from Jun.2016 to Jun.2019 in Seventh People's Hospital of Zhengzhou were analyzed retrospectively.These patients were divided into Ranibizumab group and TA group,and 30 eyes of 30 cases in each group.The two groups were treated with intravitreal injection of Ranibizumab and TA injection under posterior tenon*s capsule,respectively.All patients received combined with retinal laser photocoagulation.The efficacy between the two groups were compared at 1 month,3 months and 6 months after injection.Results BCVA in TA group was better than that in Ranibizumab group at 1 month after injection(t=4.240,P=0.044).The difference was not statistically significant in BCVA between the two groups at 3 and 6 months after treatment.At 1 month after treatment the central macular thickness(MT)in Ranibizumab group was higher that than in TA group(t=2.116,P=0.022).At 3 and 6 months after treatment,the CMT in the TA group were higher than those in Ranibizumab group(t=3.386,2.236,P=0.018,0.015).At 1 month after treatment,the intraocular pressure in Ranibizumab group was significantly higher than that before treatment(P<0.05).There was no significant change in TA group at all time points after treatment compared with that before treatment(P>0.05).Conclusion The triamcinolone acetonide injection under tenon's capsule has better efficacy than Rannibizumab,no risk of elevated intraocular pressure and the injection is simple and safe.